Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Palisade Bio (PALI) over the last 16 years, with Q3 2025 value amounting to -$2.9 million.

  • Palisade Bio's Consolidated Net Income rose 1867.19% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year increase of 2168.81%. This contributed to the annual value of -$14.9 million for FY2024, which is 1364.92% down from last year.
  • According to the latest figures from Q3 2025, Palisade Bio's Consolidated Net Income is -$2.9 million, which was up 1867.19% from -$2.8 million recorded in Q2 2025.
  • In the past 5 years, Palisade Bio's Consolidated Net Income ranged from a high of -$2.3 million in Q1 2025 and a low of -$33.5 million during Q2 2021
  • Over the past 5 years, Palisade Bio's median Consolidated Net Income value was -$3.6 million (recorded in 2023), while the average stood at -$5.1 million.
  • As far as peak fluctuations go, Palisade Bio's Consolidated Net Income plummeted by 171888.15% in 2021, and later surged by 8932.65% in 2022.
  • Palisade Bio's Consolidated Net Income (Quarter) stood at -$3.0 million in 2021, then fell by 26.59% to -$3.9 million in 2022, then grew by 18.0% to -$3.2 million in 2023, then dropped by 7.19% to -$3.4 million in 2024, then rose by 13.53% to -$2.9 million in 2025.
  • Its last three reported values are -$2.9 million in Q3 2025, -$2.8 million for Q2 2025, and -$2.3 million during Q1 2025.